Elevated levels of 4-hydroxynonenal-histidine Michael adduct in the hippocampi of patients with Alzheimer's disease

Biomedical Research

Volumn 30, Issue 4, 2009, Pages 227-233

  Fukuda, Mitsugu ^a   Kanou, Fumihisa ^b   Shimada, Nobuko ^a   Sawabe, Motoji ^c   Saito, Yuko ^a,c   Murayama, Shigeo ^a   Hashimoto, Masakatsu ^b   Maruyama, Naoki ^a   Ishigami, Akihito ^a,d  

^a TOKYO METROPOLITAN INSTITUTE OF GERONTOLOGY   (Japan)

^b SHIMA Microbio Laboratory   (Japan)

^c Tokyo Metropolitan Institute of Gerontology   (Japan)

^d TOHO UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

4 HYDROXYNONENAL; ANTIBODY; HISTIDINE; LIPID; POLYUNSATURATED FATTY ACID; PYRROLE;

ADULT; ALZHEIMER DISEASE; ARTICLE; BRAIN LEVEL; CASE REPORT; CONTROLLED STUDY; FEMALE; HIPPOCAMPUS; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; LIPID PEROXIDATION; MALE; NEUROPATHOLOGY; PERIKARYON; PYRAMIDAL NERVE CELL;

ALDEHYDES; ALZHEIMER DISEASE; BRAIN CHEMISTRY; FATTY ACIDS, UNSATURATED; FEMALE; HISTIDINE; HUMANS; LIPID PEROXIDATION; MALE; PYRAMIDAL CELLS;

EID: 70349386042     PISSN: 03886107     EISSN: 1880313X     Source Type: Journal    
DOI: 10.2220/biomedres.30.227     Document Type: Article

References (29)

1. Consensus recommendations for the postmortem diagnosis of Alzheimer's disease (1997). The National Institute on Aging, and Reagan Institute Working Group on Diagnostic Criteria for the Neuropathological Assessment of Alzheimer's Disease. Neurobiol Aging 18, S1-2.
2. Abdul HM and Butterfield DA (2007) Involvement of PI3K/PKG/ERK1/2 signaling pathways in cortical neurons to trigger protection by cotreatment of acetyl-L-camitine and alpha-lipoic acid against HNE-mediated oxidative stress and neurotoxicity: implications for Alzheimer's disease. Free Radic Biol Med 42, 371-384.
3. Amarnath V, Valentine WM, Montine TJ, Patterson WH, Amarnath Y, Bassett CN and Graham DG (1998) Reactions of 4-hydroxy-2(E)-nonenal and related aldehydes with proteins studied by carbon-13 nuclear magnetic resonance spectroscopy. Chem Res Toxicol 11, 317-328.
4. Dei R, Takeda A, Niwa H, Li M, Nakagomi Y, Watanabe M, Inagaki T, Washimi Y, Yasuda Y, Horie K, Miyata T and Sobue G (2002) Lipid peroxidation and advanced glycation end products in the brain in normal aging and in Alzheimer's disease. Acta Neuropathol 104, 113-122.
5. Esterbauer H, Schaur RJ and Zollner H (1991) Chemistry and biochemistry of 4-hydroxynonenal, malonaldehyde and related aldehydes. Free Radic Biol Med 11, 81-128.
6. Ji C, Amarnath V, Pietenpol JA and Marnett LJ (2001) 4-hydroxynonenal induces apoptosis via caspase-3 activation and cytochrome c release. Chem Res Toxicol 14, 1090-1096.
7. Kokubo J, Nagatani N, Hiroki K, Kuroiwa K, Watanabe N and Arai T (2008) Mechanism of destruction of microtubule structures by 4-hydroxy-2-nonenal. Cell Struct Funct 33, 51-59.
8. Kruman I, Bruce-Keller AJ, Bredesen D, Waeg G and Mattson MP (1997) Evidence that 4-hydroxynonenal mediates oxidative stress-induced neuronal apoptosis. J Neurosci 17, 5089-5100.
9. Liu X, Lovell MA and Lynn BC (2005) Development of a method for quantification of acrolein-deoxyguanosine adducts in DNA using isotope dilution-capillary LC/MS/MS and its application to human brain tissue. Anal Chem 77, 5982-5989.
10. Lovell MA, Ehmann WD, Butler SM and Markesbery WR (1995) Elevated thiobarbituric acid-reactive substances and antioxidant enzyme activity in the brain in Alzheimer's disease. Neurology 45, 1594-1601.
11. Lovell MA and Markesbery WR (2007) Oxidative damage in mild cognitive impairment and early Alzheimer's disease. J Neurosci Res 85, 3036-3040.
12. Lovell MA, Xie C and Markesbery WR (2001) Acrolein is increased in Alzheimer's disease brain and is toxic to primary hippocampal cultures. Neurobiol Aging 22, 187-194.
13. Mamelak M (2007) Alzheimer' s disease, oxidative stress and gammahydroxybutyrate. Neurobiol Aging 28, 1340-1360.
14. Mani RB, Lohr JB and Jeste DV (1986) Hippocampal pyramidal cells and aging in the human: a quantitative study of neuronal loss in sectors CA1 to CA4. Exp Neurol 94, 29-40.
15. Mark RJ, Lovell MA, Markesbery WR, Uchida K and Mattson MP (1997) A role for 4-hydroxynonenal, an aldehydic product of lipid peroxidation, in disruption of ion homeostasis and neuronal death induced by amyloid beta-peptioe. J Neurochem 68, 255-264.
16. Markesbery WR, Kryscio RJ, Lovell MA and Morrow JD (2005) Lipid peroxidation is an early event in the brain in amnestic mild cognitive impairment. Ann Neurol 58, 730-735.
17. Markesbery WR and Lovell MA (1998) Four-hydroxynonenal, a product of lipid peroxidation, is increased in the brain in Alzheimer's disease. Neurobiol Aging 19, 33-36.
18. Montine KS, Olson SJ, Amarnath V, Whetsell WO, Jr., Graham DG and Montine TJ (1997) Immunohistochemical detection of 4-hydroxy-2-nonenal adducts in Alzheimer's disease is associated with inheritance of APOE4. Am J Pathol 150, 437-443.
19. Montine KS, Reich E, Neely MD, Sidell KR, Olson SJ, Markesbery WR and Montine TJ (1998) Distribution of reducible 4-hydroxynonenal adduct immunoreactivity in Alzheimer disease is associated with APOE genotype. J Neuropathol Exp Neurol 57, 415-425.
20. Neely MD, Sidell KR, Graham DG and Montine TJ (1999) The lipid peroxidation product 4-hydroxynonenal inhibits neurite outgrowth, disrupts neuronal microtubules, and modifies cellular tubulin. J Neurochem 72, 2323-2333.
21. Porter NA, Caldwell SE and Mills KA (1995) Mechanisms of free radical oxidation of unsaturated lipids. Lipids 30, 277-290.
22. Pratico D, V MYL, Trojanowski JQ, Rokach J and Fitzgerald GA (1998) Increased F2-isoprostanes in Alzheimer's disease: evidence for enhanced lipid peroxidation in vivo. FASEB J 12, 1777-1783.
23. Reich EE, Markesbery WR, Roberts LJ, 2nd, Swift LL, Morrow JD and Montine TJ (2001) Brain regional quantification of F-ring and D-/E-ring isoprostanes and neuroprostanes in Alzheimer's disease. Am J Pathol 158, 293-297.
24. Sayre LM, Zelasko DA, Harris PL, Perry G, Salomon RG and Smith MA (1997) 4-Hydroxynonenal-derived advanced lipid peroxidation end products are increased in Alzheimer's disease. J Neurochem 68, 2092-2097.
25. Smith MA (1998) Alzheimer disease. Int Rev Neurobiol 42, 1-54.
26. Tanaka T, Nishiyama Y, Okada K, Hirota K, Matsui M, Yodoi J, Hiai H and Toyokuni S (1997) Induction and nuclear translocation of thioredoxin by oxidative damage in the mouse kidney: independence of tubular necrosis and sulfhydryl depletion. Lab Invest 77, 145-155.
27. Uchida K and Stadtman ER (1992) Modification of histidine residues in proteins by reaction with 4-hydroxynonenal. Proc Natl Acad Sci USA 89, 4544-4548.
28. Williams TI, Lynn BC, Markesbery WR and Lovell MA (2006) Increased levels of 4-bydroxynonenal and acrolein, neurotoxic markers of lipid peroxidation, in the brain in Mild Cognitive Impairment and early Alzheimer's disease. Neurobiol Aging 27, 1094-1099.
29. Xiao Y, Huang Y and Chen ZY (2005) Distribution, depletion and recovery of docosahexaenoic acid are region-specific in rat brain. Br J Nutr 94, 544-550.